Phase 2 Hormone Clinical Trials
44 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 44 trials
Recruiting
Phase 1Phase 2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals181 enrolled25 locationsNCT07190300
Recruiting
Phase 1Phase 2
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc.92 enrolled12 locationsNCT07287917
Recruiting
Phase 2
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
Adult Growth Hormone DeficiencyGulf War Syndrome
Baylor College of Medicine20 enrolled2 locationsNCT05355272
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaHormone Receptor-Positive Breast Carcinoma+1 more
City of Hope Medical Center43 enrolled6 locationsNCT04305834
Recruiting
Phase 2
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone Sensitive Prostate Cancer
Novartis Pharmaceuticals150 enrolled65 locationsNCT06991556
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.218 enrolled33 locationsNCT07005154
Recruiting
Phase 1Phase 2
VS-6766+Abema+Fulv in Met HR+/HER- BC
Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks63 enrolled3 locationsNCT05608252
Recruiting
Phase 2
ETHAN - ET for Male BC
Hormone Receptor-Positive Breast CancerMale Breast CancerHormone Receptor-Negative Breast Carcinoma
Jose Pablo Leone60 enrolled8 locationsNCT05501704
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Tumor+1 more
SOLTI Breast Cancer Research Group96 enrolled15 locationsNCT05982093
Recruiting
Phase 1Phase 2
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine152 enrolled3 locationsNCT06374459
Recruiting
Phase 2
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+3 more
University of Washington60 enrolled2 locationsNCT06179303
Recruiting
Phase 2
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+2 more
UNC Lineberger Comprehensive Cancer Center700 enrolled1 locationNCT07340541
Recruiting
Phase 2
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
HER2-negative Breast CancerHormone Receptor-Positive Breast CancerLocoregional Recurrence
Oana Danciu200 enrolled20 locationsNCT05467891
Recruiting
Phase 2
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington40 enrolled1 locationNCT07112053
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Advanced Breast CancerHormone Receptor-Positive Breast CarcinomaAdvanced Breast Carcinoma
MedSIR200 enrolled56 locationsNCT06486883
Recruiting
Phase 2
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
National Cancer Centre, Singapore40 enrolled1 locationNCT05286437
Recruiting
Phase 1Phase 2
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080